Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis

Key Inclusion Criteria:

1. Male or female, over the age of 18

2. Chronic atopic dermatitis (AD) diagnosed at least 1 year.

3. Subject with EASI score ≥16, IGA ≥ 3 (on the 0 to 4 IGA scale, in which 3 ismoderate and 4 is severe), ≥ 10% body surface area (BSA) of AD involvement.

4. Subjects with a history of an inadequate response or medically inappropriate use oftopical drug treatment within 6 months.

Key Exclusion Criteria:

1. Inadequate washout period for prior drug therapy (eg. corticosteroids,immunosuppressive/ immunomodulating, biologics, phototherapy, Chinese traditionalmedicine, anti-infective agents).

2. History of exposure to active TB, and/or history or current evidence of TBinfection.

3. Positive serology results at Screening for hepatitis B, hepatitis C or HIV.

4. Any history of vernal keratoconjunctivitis (VKC) or atopic keratoconjunctivitis (AKC) within 6 months before the baseline visit.

5. History of clinical parasite infection, recent or planned travel to an area withendemic parasite infection within 6 months before the Screening visit

6. Any medical or psychiatric condition, laboratory, or ECG parameter which, in theopinion of the Investigator or the Sponsor's medical monitor, would place thesubject at risk, interfere with participation in the study, or interfere with theinterpretation of study results.